de Benito-Llopis Laura, Teus Miguel A, Hernández-Verdejo José L
Vissum Madrid, Madrid, Spain.
Am J Ophthalmol. 2009 Jan;147(1):71-76.e2. doi: 10.1016/j.ajo.2008.07.015. Epub 2008 Sep 6.
To compare the residual refraction and visual results between the three- and six-month postoperative visits to detect the optimal moment for enhancement after myopic laser epithelial keratomileusis (LASEK) with mitomycin C (MMC).
Nonrandomized, interventional, prospective study.
One hundred and forty-one consecutive eyes that underwent LASEK with MMC to correct their myopia using the Esiris excimer laser (Schwind Eye Tech Solutions, Kleinostheim, Germany), and that showed three months postoperatively a residual defect or a suboptimal uncorrected visual acuity (UCVA) or best spectacle-corrected visual acuity (BSCVA) were included in the study. We compared the residual spherical refraction and cylinder, the UCVA, and the BSCVA between the three- and six-month postoperative examinations.
Preoperative spherical refraction was -5.2 +/- 2.90 diopters (D). Preoperative cylinder was -1.66 +/- 1.20 D. The residual sphere was +0.43 +/- 0.90 D three months and +0.21 +/- 0.90 D six months after surgery (P = .0001). The cylinder was -0.71 +/- 0.60 D and -0.67 +/- 0.60 D, respectively (P = .4). The UCVA was 0.75 +/- 0.2 and 0.81 +/- 0.2 (P = .0001) and the BSCVA was 0.94 +/- 0.1 and 1.01 +/- 0.1 (P = .0001), respectively. Those patients with a myopic defect (sphere or cylinder) three months postoperatively did not show any significant change in UCVA or refractive defect six months after surgery, while those with a hyperopic defect (sphere or cylinder) showed an improvement in UCVA and residual refraction six months postoperatively (P < .05).
Our results suggest that retreatment after myopic LASEK with MMC may be performed three months after surgery when the residual refraction is myopic, but it seems wise to wait at least six months after surgery when the residual refraction is hyperopic.
比较近视准分子激光上皮下角膜磨镶术(LASEK)联合丝裂霉素C(MMC)术后3个月和6个月时的残余屈光度及视觉效果,以确定增效的最佳时机。
非随机、干预性、前瞻性研究。
连续纳入141只接受MMC辅助的LASEK手术以矫正近视的眼睛,使用德国施温德眼科技术解决方案公司的Esiris准分子激光。这些眼睛术后3个月时存在残余屈光不正或最佳矫正视力(BCVA)或未矫正视力(UCVA)未达最佳状态。我们比较了术后3个月和6个月时的残余球镜度、柱镜度、UCVA及BCVA。
术前球镜度为-5.2±2.90屈光度(D)。术前柱镜度为-1.66±1.20D。术后3个月残余球镜度为+0.43±0.90D,术后6个月为+0.21±0.90D(P = 0.0001)。柱镜度分别为-0.71±0.60D和-0.67±0.60D(P = 0.4)。UCVA分别为0.75±0.2和0.81±0.2(P = 0.0001),BCVA分别为0.94±0.1和1.01±0.1(P = 0.0001)。术后3个月存在近视性屈光不正(球镜或柱镜)的患者术后6个月UCVA或屈光不正无显著变化,而存在远视性屈光不正(球镜或柱镜)的患者术后6个月UCVA和残余屈光度有所改善(P < 0.05)。
我们的结果表明,MMC辅助下近视LASEK术后,若残余屈光度为近视,可在术后3个月进行再次治疗;但若残余屈光度为远视,术后至少等待6个月似乎更为明智。